SeaStar Medical Holding Corp
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Its proprietary Selective Cytopheretic Device (SCD) technology neutralizes over-active immune cells to stop cytokine storms and reduce hyperinflammation on vital organs. The company's first commercial product, QUELIMMUNE (SCD-PED), received FDA approval in 2024 for treating life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients. It is also developing NEUTRALIZE-AKI for adult patients and maintains its headquarters in Denver, Colorado.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- FDA approved QUELIMMUNE therapy in 2024 for pediatric AKI due to sepsis.
- SCD technology awarded Breakthrough Device Designation for multiple indications.
- Reported $3.7 million net loss and $7.0 million cash position as of mid-2026.
- Sponsors educational initiatives for pediatric AKI critical care best practices.
Ask StreetZero about SeaStar Medical Holding Corp
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account